Nicotine does relieve pain in the short term. A meta-analysis pooling decades of human experiments found that nicotine produces a small-to-medium acute analgesic effect, raising both pain thresholds and pain tolerance across multiple delivery methods. But the story flips with repeated use: people who smoke regularly tend to report significantly more pain than nonsmokers, not less. That contradiction sits at the heart of nicotine’s complicated relationship with pain, and understanding it matters for anyone who smokes, vapes, or is considering nicotine-based therapies.
How Nicotine Interacts With Pain Pathways
Nicotine binds to a family of receptors in the nervous system called nicotinic acetylcholine receptors. These receptors are scattered throughout the brain and spinal cord but also sit on sensory neurons that carry pain signals from the body. When nicotine activates them, it can dampen the transmission of pain signals at several points along the chain. Research has identified multiple receptor subtypes on primary sensory neurons in the dorsal root ganglia, the clusters of nerve cell bodies near the spinal cord where pain signals first get processed on their way to the brain.1PubMed. Dorsal root ganglion neurons express multiple nicotinic acetylcholine receptor subtypes
Two receptor subtypes get the most attention in pain research. One, called alpha-4-beta-2, is widely expressed in the brain and spinal cord and appears to mediate much of the classic analgesic effect of nicotine. The other, called alpha-7, plays a role in controlling inflammation and seems especially relevant to chronic inflammatory and neuropathic pain.2PubMed. Functional role of alpha7 nicotinic receptor in chronic neuropathic and inflammatory pain: studies in transgenic mice The alpha-7 receptor is also connected to the body’s own opioid system. Research suggests that nicotine’s pain-relieving effects are partly mediated by triggering endogenous opioid release through this receptor.3Journal of Pharmacological Sciences. Current Perspective Nicotine Effects and the Endogenous Opioid System In other words, nicotine does not just block pain on its own; it also recruits the brain’s built-in painkilling machinery.
Beyond these receptor-level effects, nicotine influences the dopamine system, which shapes how the brain emotionally processes pain. Dopamine receptors in reward circuits help regulate the balance between pain sensation and the feeling of relief, and nicotine’s well-known ability to flood those circuits with dopamine likely contributes to the subjective sense that pain feels less bothersome after a cigarette, even if the raw sensory signal has not changed much.
What Happens in Controlled Human Experiments
The clearest evidence for nicotine’s acute pain-relieving properties comes from laboratory studies where researchers apply a painful stimulus and measure how people respond with and without nicotine. A meta-analysis that combined results from multiple such studies found that nicotine delivered via cigarette smoke, patches, or nasal spray produced a statistically meaningful increase in both pain threshold (the point at which something starts to hurt) and pain tolerance (how long someone can endure it). The overall effect size was small to medium.4PubMed Central. Acute Analgesic Effects of Nicotine and Tobacco in Humans: A Meta-Analysis
A randomized, placebo-controlled study extended this work to electronic cigarettes. When participants vaped nicotine versus a placebo e-liquid, nicotine increased cold-pressor pain tolerance as well as ischemic pain threshold and tolerance. Interestingly, nicotine had no effect on a test called temporal summation, which mimics the “wind-up” process thought to underlie some chronic pain states.5Psychopharmacology. Acute Analgesic Effect of Nicotine Vaping Using Three Experimental Pain Induction Tasks: a Randomized, Placebo-controlled Laboratory Study That distinction hints at an important nuance: nicotine’s acute benefit may help with sudden, sharp pain but not with the types of pain processing that drive persistent pain conditions.
These are lab findings, though, and lab pain is not real-world pain. The stimuli are brief and controlled. Participants know the pain will end. Anxiety, sleep, mood, and all the other factors that shape clinical pain are mostly held constant. The evidence tells us nicotine genuinely changes pain processing in the moment, but it says less about what happens when someone uses nicotine day after day while dealing with ongoing pain.
Why Smokers Report More Pain, Not Less
If nicotine is a painkiller, you might expect regular smokers to have less pain than nonsmokers. The opposite is true. A large analysis using data from a comprehensive patient registry found that smokers presenting at pain clinics reported significantly higher current pain intensity, higher average pain over the preceding week, and higher worst pain compared with nonsmokers. These differences persisted at follow-up, meaning they were not just a snapshot of a bad day.6PubMed Central. Effects of smoking on patients with chronic pain: a propensity-weighted analysis on the Collaborative Health Outcomes Information Registry
Several things likely drive this paradox. Smoking accelerates tissue damage, slows healing, reduces blood flow, and promotes systemic inflammation, all of which independently worsen pain. But the pharmacology of nicotine itself also contributes, through a mechanism that takes center stage once we look at what happens between doses.
Withdrawal and the Pain Rebound
The flip side of nicotine’s acute pain relief is withdrawal-induced hyperalgesia: when nicotine levels drop, pain sensitivity rises above where it would have been without nicotine in the first place. In one study, daily smokers who went through extended nicotine deprivation showed increased pain intensity ratings, greater neurogenic inflammation, and heightened sensitivity to mechanical stimulation compared with smokers who continued smoking.7PubMed Central. Nicotine deprivation increases pain intensity, neurogenic inflammation, and mechanical hyperalgesia among daily tobacco smokers Both central mechanisms in the brain and peripheral mechanisms in the skin and nerves appeared to be involved.
Animal research has helped clarify what is going on at a molecular level. In rats, nicotine withdrawal significantly lowered mechanical and thermal pain thresholds, and this was linked to downregulation of serotonin-based pain-suppressing pathways descending from the brainstem.8PubMed. Nicotine withdrawal induces hyperalgesia via downregulation of descending serotonergic pathway in the nucleus raphe magnus Another rodent study found that nicotine and cigarette smoke exposure induced hyperalgesia, lowered pain tolerance, and increased expression of a protein associated with nerve sensitization.9PubMed. Hyperalgesia and Neuropathic Pain Mechanism in Rodent Models of Cigarette Smoking- and Nicotine-Induced Precipitated Withdrawal Study
This creates a vicious cycle for regular users. Each dose of nicotine provides temporary relief, but between doses, pain sensitivity creeps upward. Over time the “relief” a smoker feels from lighting up is increasingly just the reversal of withdrawal-driven pain, not genuine analgesia relative to a nicotine-free baseline. For someone living with chronic pain, smoking can feel like it helps while actually making the underlying problem worse.
Tolerance and Receptor Desensitization
Closely related to withdrawal hyperalgesia is the phenomenon of tolerance. With repeated nicotine exposure, the receptors that mediate pain relief become desensitized and eventually upregulate in number, which paradoxically makes the system more excitable when nicotine is absent. A systematic review and meta-analysis of human studies concluded that despite providing short-term pain relief, prolonged nicotine exposure leads to tolerance and increased pain sensitivity due to receptor desensitization and accompanying changes in neural circuitry.10PubMed Central. The Anti-Nociceptive Effects of Nicotine in Humans: A Systematic Review and Meta-Analysis A Japanese consensus statement on smoking and pain reached the same conclusion, noting that the acute analgesic properties of nicotine are undermined by desensitization and neuronal plastic changes with long-term use.11PubMed Central. Consensus statement on smoking cessation in patients with pain
The analogy to opioid tolerance is worth noting. Just as chronic opioid use can produce opioid-induced hyperalgesia, chronic nicotine use can produce nicotine-induced hyperalgesia through similar adaptive changes in the nervous system. The acute drug effect and the chronic drug effect point in opposite directions. Researchers studying nicotine for neuropathy models have noted that nicotine’s analgesic profile “is a matter of debate since the analgesic properties may be impaired by receptor desensitization and tolerance.”12European Journal of Pharmacology. Nicotine is a pain reliever in trauma- and chemotherapy-induced neuropathy models
Nicotine Patches After Surgery
One clinical setting where nicotine’s acute analgesic effect has been tested is postoperative pain management. The idea is appealing: a nicotine patch applied around the time of surgery could reduce pain and perhaps cut opioid use during recovery. A pilot dose-ranging study found that transdermal nicotine at doses of 5 to 15 milligrams reduced postoperative pain scores after general surgical procedures, but it did not decrease the total amount of opioid analgesics patients needed or reduce opioid-related side effects like nausea.13PubMed. Transdermal nicotine patch for postoperative pain management: a pilot dose-ranging study
A trial comparing nicotine patches to melatonin patches and placebo after laparoscopic gallbladder removal reported more encouraging results. The nicotine group had significantly lower pain scores in the hours after surgery, needed less rescue pain medication, and reported higher satisfaction.14Egyptian Journal of Anaesthesia. Comparative study between transdermal nicotine and melatonin patches on postoperative pain relief after laparoscopic cholecystectomy, a double-blind, placebo-controlled trial But a recent systematic review that pulled together the broader surgical literature noted that while perioperative nicotine showed promise for reducing pain, nausea, and vomiting in some studies, results were inconsistent across different patient groups, dosing forms, and dosages, making firm clinical recommendations premature.15PubMed Central. Perioperative Nicotine for Postoperative Pain and Nausea: A Systematic Review with Clinical and Methodological Insights
An important caveat in surgical settings is that the patients most likely to benefit from a nicotine patch are nonsmokers, who have not developed tolerance. In regular smokers, the same patch may simply prevent withdrawal-induced hyperalgesia rather than provide additional analgesia. Clinicians have to weigh these competing scenarios when designing protocols, which partly explains the mixed results across trials.
Sex Differences in Nicotine Analgesia
The pain-relieving effect of nicotine is not identical in everyone, and biological sex appears to matter. Animal research has found that nicotine produced greater increases in pain tolerance in female rats than in males across a range of doses.16PubMed. Sex differences in cocaine- and nicotine-induced antinociception in the rat Nicotine also reduced spontaneous movement more in females, suggesting broader nervous system effects that differed by sex.
Human data on sex differences in nicotine analgesia are thinner, and the meta-analytic literature has not consistently broken results down by sex in a way that gives definitive answers. But the animal findings align with broader patterns in pain research: women and men differ in pain sensitivity, endogenous opioid function, and responses to many analgesic drugs. If nicotine-based pain treatments ever reach the clinic, dosing may need to account for these differences.
What Nicotine Does to Nerve Regeneration
Beyond its effects on pain signaling, nicotine appears to influence the structural biology of injured nerves. In two rat nerve injury models, nicotine administration significantly reduced mechanical allodynia and thermal hyperalgesia for weeks after surgery. But it also inhibited nerve regeneration and reduced expression of a protein called GAP43 that is critical for nerve regrowth. Blocking the alpha-7 receptor reversed both effects, restoring nerve growth while also eliminating the pain relief.17eNeuro. Nicotine Decreases Nerve Regeneration and Pain Behaviors via PTEN and Downstream Inflammation-Related Pathway in Two Rat Nerve Injury Models
This is a meaningful trade-off. Nicotine may reduce neuropathic pain partly by preventing the disorderly nerve regrowth that generates pain signals in the first place, but it does so at the cost of impairing the normal healing process. For someone recovering from a nerve injury or surgery, that could mean less pain now but slower functional recovery later. It also raises questions about long-term nicotine use in conditions where nerve repair is desirable.
The Poison Frog That Inspired a New Class of Painkillers
Some of the strongest evidence that nicotinic receptors represent a real analgesic target comes not from nicotine itself but from a compound found in nature. Epibatidine, an alkaloid isolated from the skin of an Ecuadorian poison frog, acts on nicotinic receptors and is several hundred times more potent as a painkiller than morphine.18PubMed. Epibatidine and its analogues as nicotinic acetylcholine receptor agonist: an update That discovery, made in the early 1990s, galvanized pharmaceutical interest in designing drugs that could hit the same receptors with greater selectivity and fewer side effects.
Epibatidine itself is far too toxic for human use; its lethal dose is close to its analgesic dose. But it served as a proof of concept that non-opioid painkillers targeting nicotinic receptors were biologically plausible. The challenge has been engineering compounds that separate the pain relief from the toxicity and from nicotine’s addictive properties.
Drug Development Targeting Nicotinic Receptors
Pharmaceutical companies have spent years trying to turn nicotinic receptor research into practical painkillers. One compound, ABT-594, showed efficacy against diabetic nerve pain in clinical trials but came with significant tolerability problems, including nausea and other side effects rooted in its broad nicotinic activity.19PAIN. Efficacy and safety of the α4β2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain A more selective follow-up compound, ABT-894, was better tolerated but failed to separate from placebo in treating the same condition, illustrating the difficulty of the balancing act.
In animal models, ABT-594 showed another interesting property: it selectively enhanced the painkilling effects of gabapentin, a widely used nerve-pain drug, at doses that had minimal effects on their own.20PubMed. Selective potentiation of gabapentin-mediated antinociception in the rat formalin test by the nicotinic acetylcholine receptor agonist ABT-594 That combination approach, using a nicotinic agent not as a standalone painkiller but as a booster for existing drugs, may be more realistic than trying to replace opioids outright. Research in this area continues, though no nicotinic receptor agonist has yet reached widespread clinical use for pain.
The path from epibatidine to a usable drug has been described as “a winding road,” and that characterization remains accurate.21PubMed Central. Neuronal nicotinic receptors as analgesic targets: it’s a winding road The receptors are undeniably involved in pain modulation, and highly selective compounds continue to show promise in animal models. But translating that into a pill a doctor can prescribe has proven stubbornly difficult, largely because the same receptor family manages so many different functions across the nervous system.
Prenatal Nicotine Exposure and Later Pain
One finding that often surprises people is that nicotine’s effects on pain may extend across generations. A study following children into adolescence found that those whose mothers smoked during pregnancy reported more musculoskeletal pain sites at age 16 than children of nonsmoking mothers. The link appeared to be partly mediated by behavioral problems in childhood, suggesting the mechanism involves developmental effects on the nervous system rather than a simple pharmacological carryover.22Oxford Academic (Nicotine & Tobacco Research). Maternal Smoking During Pregnancy Is Associated With Offspring’s Musculoskeletal Pain in Adolescence: Structural Equation Modeling
This is a single observational study and should be interpreted cautiously, but it fits with a growing body of research suggesting that prenatal nicotine exposure can alter how the developing nervous system processes sensory information. Animal models have shown that nicotine exposure during critical windows of brain development changes the expression and distribution of nicotinic receptors in ways that persist long after the drug is gone. Whether those changes translate into clinically meaningful differences in pain sensitivity across a human lifetime remains an open question, but the early data are concerning enough to add another reason to the long list of arguments against smoking during pregnancy.
What This Means If You Use Nicotine for Pain
If you smoke or vape partly because you feel it helps with pain, the science suggests you are not imagining the immediate relief. Nicotine genuinely modulates pain processing in the short term, and the effect is measurable across multiple types of experimental pain. But the relief is modest in magnitude, and it comes packaged with a tolerance-and-withdrawal cycle that, over weeks and months, is likely making your baseline pain worse.
Quitting will probably hurt more before it hurts less. The withdrawal hyperalgesia documented in both human and animal studies means that the first days and weeks after stopping nicotine can involve a real, physiologically driven increase in pain sensitivity. Knowing this in advance can help you plan: working with a doctor to adjust pain management temporarily during a quit attempt, for instance, rather than interpreting the increased pain as evidence that you “need” nicotine. The Japanese consensus statement on smoking and pain explicitly recommends that clinicians anticipate and address withdrawal-related pain increases when helping patients quit.11PubMed Central. Consensus statement on smoking cessation in patients with pain
For researchers and clinicians, the more interesting question is whether nicotinic receptor science can eventually produce a painkiller that captures the acute benefit without the addiction, tolerance, and tissue damage. The frog-toxin-to-pharmacy pipeline has been slower than anyone hoped, but the biological target remains one of the more promising non-opioid avenues in pain pharmacology. If that research pays off, the answer to whether nicotine relieves pain will become less relevant, replaced by a more useful question about whether something inspired by nicotine can relieve pain safely.